SHH and neoplasm: In agreement with the reduced tumor growth rates observed (Figure 2C), the immunohistochemical analysis of Ki67, a proliferation marker and prognosis factor used in the examination of the pathology of tumors, indicate a 20% reduction in the Ki67 levels in tumors treated with SHH-ligand (Figure 2F–G).